Phathom Pharmaceuticals Inc’s filing revealed that its Chief Operating Officer Nabulsi Azmi unloaded Company’s shares for reported $0.13 million on Jul 15 ’24. In the deal valued at $11.72 per share,10,901 shares were sold. As a result of this transaction, Nabulsi Azmi now holds 240,421 shares worth roughly $2.13 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Henderson Molly sold 4,325 shares, generating $50,689 in total proceeds. Upon selling the shares at $11.72, the CFO and CBO now owns 99,447 shares.
Before that, Curran Terrie sold 33,848 shares. Phathom Pharmaceuticals Inc shares valued at $396,699 were divested by the President and Chief Executive at a price of $11.72 per share. As a result of the transaction, Curran Terrie now holds 377,734 shares, worth roughly $3.34 million.
Stifel initiated its Phathom Pharmaceuticals Inc [PHAT] rating to a Buy in a research note published on May 03, 2024; the price target was $24. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering PHAT with “Buy” recommendation on August 09, 2023. Evercore ISI revised its rating on May 11, 2023. It rated PHAT as “an Outperform” which previously was an “an In-line”.
Price Performance Review of PHAT
On Tuesday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock jump 1.49% to $8.84. Over the last five days, the stock has lost -2.75%. Phathom Pharmaceuticals Inc shares have fallen nearly -3.18% since the year began. Nevertheless, the stocks have risen 21.10% over the past one year. While a 52-week high of $19.71 was reached on 09/19/24, a 52-week low of $6.07 was recorded on 02/13/24. SMA at 50 days reached $14.49, while 200 days put it at $12.25.
Levels Of Support And Resistance For PHAT Stock
The 24-hour chart illustrates a support level at 8.57, which if violated will result in even more drops to 8.29. On the upside, there is a resistance level at 9.15. A further resistance level may holdings at 9.45. The Relative Strength Index (RSI) on the 14-day chart is 29.67, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.50%. Stochastics %K at 10.02% indicates the stock is a buying.
How much short interest is there in Phathom Pharmaceuticals Inc?
A steep rise in short interest was recorded in Phathom Pharmaceuticals Inc stocks on 2024-11-15, dropping by -2.89 million shares to a total of 14.66 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 17.56 million shares. There was a decline of -19.72%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 13, 2023 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.
